Skip to main content
OpenTrials
Completed

NCT Number: NCT02509858

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

We investigated the effect of the administration of small doses of thyroxine to healthy humans and patients with type 2 diabetes on postprandial forearm muscle glucose uptake, insulin sensitivity indices, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The present open-labeled, randomized and placebo-controlled study was undertaken in euthyroid type 2 diabetic patients and healthy humans, to examine the effect of administration of small doses of thyroxine within the euthyroid range, on muscle glucose disposal, postprandial insulin sensitivity, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.This was investigated with the arteriovenous-difference technique after the consumption of a mixed meal and the in vitro study of a glucose analogue(6-NBDG) uptake by the peripheral monocytes.

Subjects and Methods: Eleven euthyroid, treatment naive, type-2 diabetic patients with a micronodular texture of the thyroid gland and eleven healthy euthyroid subjects, were studied before and after administration of 50 μg of thyroxine once daily for 2 months. In parallel, a placebo group was also studied. Eleven euthyroid treatment-naïve subjects with type 2 diabetes and a micronodular texture of the thyroid gland, matched for age, sex, BMI, and basal thyroid function, were studied before and after administration of a placebo, once daily for 2 months.

Experimental protocol: All subjects were admitted to the hospital at 0700 h after an overnight fast and had the radial artery (A) and a forearm deep vein (V) catheterized. A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein) was given at least 1 h after catheter insertion and was consumed within 20 min. Blood samples were drawn from both sites before the meal (at -30 and 0 min) and at 30- to 60-min intervals for 300 min thereafter for measurements of thyroid hormones,glucose, total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides, Apolipoprotein A1, Apolipoprotein BII and Lp(a).Forearm blood flow was measured with strain-gauge plethysmography. After the first meal tolerance test, treatment with 50μg of thyroxine or placebo, once daily, was initiated for a 2-month period. Then a second identical test was repeated. Special care was taken in order to avoid the induction of subclinical hyperthyroidism, that is suppression of TSH below 0.27 μU/ml, as it has recently been shown that the latter is also an insulin-resistant condition.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland.
  • Recreationally active
  • With stable body weight and diet during the last two months.

Exclusion criteria

  • Any systemic disease(besides glucose abnormalities)
  • Any medication therapy
  • Diabetic complications

Treatment and study plan

Thyroxine

Drug

treatment with 50μg of thyroxine once daily for two months.

Other names: T4

Placebo

Drug

treatment with 50μg of placebo, once daily, for two months.

A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)

Other

Primary outcomes

  1. area under the glucose uptake versus time curve-AUC

    Time frame: Time Frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    Muscle glucose uptake following meal ingestion

Secondary outcomes

  1. Plasma glucose levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  2. Plasma insulin levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  3. Plasma triglyceride levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  4. Plasma total cholesterol levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  5. Plasma LDL-cholesterol levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  6. Plasma HDL-cholesterol levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  7. Plasma Apo-A levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  8. Plasma Apo-B levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  9. Plasma Lp(α) levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  10. Plasma NEFA levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  11. Plasma glycerol levels following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  12. Muscle blood flow following meal ingestion

    Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

    area under the plasma concentration versus time curve-AUC

  13. Plasma thyroid hormones

    Time frame: baseline

    measure of plasma concentration

  14. glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG

    Time frame: baseline to 600 sec

    area under the curve of 6-NBDG uptake by monocytes under insulin stimulation

  15. % GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.

    Time frame: baseline

  16. Number of participants with adverse events

    Time frame: 300 min postmeal

Sponsors and collaborators

Lead sponsor

Attikon Hospital

Other

Registry information

Official study title

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, at All Stages of Type 2 Diabetes Mellitus.

Important dates

Study start
2009
Primary completion
2014
Study completion
2015
First posted
Jul 28, 2015
Registry last updated
Jul 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.